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Abstract.  The 67-kD serum response factor (p67  sRF) 
is a ubiquitous nuclear transcription  factor that acts 
by direct binding to a consensus DNA sequence, the 
serum response element (SRE), present in the pro- 
moter region of numerous genes.  Although p67  sRF was 
initially  implicated in the activation of mitogen-stim- 
ulated genes, the identification of a sequence similar to 
SRE, the CArG box motif, competent to interact with 
SRE binding factors in many muscle-specific genes, 
has led to speculation that,  in addition to its function 
in cell proliferation,  p67  sRF may play a role in muscle 
differentiation.  Indirect immunofluorescence using 
affinity-purified antibodies specifically directed against 
p67  sRF reveals that this factor is constitutively expressed 
and localized in the nucleus of two skeletal muscle 
cell lines:  rat L6 and mouse C2 myogenic cells during 
myogenic differentiation.  This result was further con- 
firmed through immunoblotting and Northern blot anal- 
ysis. Furthermore,  specific inhibition of p67 sRF in vivo 
through microinjection of purified p67 s~ antibodies 
prevented the myoblast-myotube transition and the ex- 
pression of muscle-specific genes such as the protein 
troponin T.  We further  showed that anti-p67 sRF injec- 
tion also inhibited the expression of the myogenic fac- 
tor myogenin, implying an early requirement for 
p67  sRF in muscle differentiation.  These results demon- 
strate that p67  s~ is involved in the process of skeletal 
muscle differentiation.  The potential action of p67  sRF 
via CArG sequences is discussed. 
S 
KELETAL myogenesis constitutes a good model to study 
biochemical mechanisms regulating  cellular differen- 
tiation.  Exposure of proliferating  myoblasts to media 
lacking  mitogen induces  withdrawal  from the proliferative 
cell cycle; cells fuse to form polynucleate myotubes.  With 
fusion,  terminal  differentiation  leads  to  the  activation  of 
many  muscle-specific genes, including  those encoding the 
sarcomeric proteins such as myosin light and heavy chains, 
ot-actin, troponin I, and  troponin  T  (Nadal-Ginard,  1978; 
Caravatti et al.,  1982). 
Various reports have examined the mechanisms  governing 
tissue-specific expression  of sarcomeric  proteins  and  led 
to the identification  of potential  cis  regulatory sequences 
conserved among many muscle genes and of different trans- 
acting  factors  that  could  interact  at  these  consensus  se- 
quences. The muscle-determining  factors (MyoD, myogenin, 
Myf 5, MFR4 [also called Herculin or Myf6]) have recently 
been identified and bind to a consensus sequence CANNTG 
(the  "E  box")  present  in  the  promoter  of many  muscle- 
specific genes. Those proteins are members of the family of 
helix-loop-helix  DNA-binding proteins,  which includes the 
oncoprotein c-myc (Braun et al.,  1989; Edmonson and O1- 
son,  1989;  Wright  et  al.,  1989;  Rhodes and  Konieczny, 
1989;  Tapscott  et  al.,  1988;  Brennan  and  Olson,  1990; 
Braun et al., 1990; Miner and Wold, 1990). Ectopic expres- 
sion of these factors in nonmyogenic cell lines is sufficient 
to convert them into muscle-specific  lineage. Cotransfection 
experiments  have demonstrated that  MyoD and myogenin 
are able to transactivate  muscle-specific  genes such as mus- 
cle  creatine  kinase,  acetylcholine  receptor  ct-subunit,  or 
ot-actin (Lassar et al.,  1989; Piette et al.,  1990; Yutzey et 
al.,  1990; Wentworth  et al.,  1991). 
In addition  to the "E-box," another DNA regulatory se- 
quence, CC(A/T)6CG,  has been identified  in a number of 
muscle-specific genes, including cardiac and skeletal muscle 
actins (Minty and Kedes,  1986), dystrophin  (Klamut et al., 
1990), and myosin light chain  1/3 (Ernst et al., 1991). This 
element,  called the CArG box motif, is related to the serum 
response element  (SRE), ~ first  identified  in the upstream 
region of the c-los gene and implicated  in the induction  of 
c-los transcription  in response to cell stimulation  by serum 
or mitogens  (Treisman,  1985).  In muscle cells, this  con- 
sensus sequence has been implicated  in the regulation  of 
cardiac and skeletal actin  genes from different  species,  as 
demonstrated by deletion and mutational  analysis (Miwa and 
1. Abbreviations  used in this paper:  p67 sm~, 67-kD serum response factor; 
SRE, serum response dement. 
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1990). 
A  ubiquitous 67-kD nuclear factor, termed the serum re- 
sponse factor (p67 sRF) interacts  with the c-fos SRE and has 
been isolated as a polypeptide of molecular mass 62-67 kD 
(Treisman,  1987; Norman et al.,  1988).  Numerous studies 
have reported that CArG box and SRE can compete for the 
same binding  activity  in C2 cells (Gutafson et al.,  1988; 
Phan-Dinh-Tuy et al., 1988) and in FAF2 cells (Taylor et al., 
1989). A protein called CBF, expressed in all cell types and 
immunologically  and biochemically indistinguishable  from 
p67  s~r, has been shown  to bind to the actin  CArG boxes 
(Boxer  et  al.,  1989).  Furthermore,  Taylor  et  al.  (1989) 
demonstrated that purified p67  sRF from HeLa cells binds to 
the Xenopus cardiac actin CArG box 1 in vitro, although 
with an affinity fourfold lower than for the cytoskeletal acfin 
SRE. In addition,  several investigations  have demonstrated 
that CArG and SRE are functionally  interchangeable,  show- 
ing that these two motifs could also bind the same factor in 
vivo (Taylor et al.,  1989; Tuil et al.,  1990); this factor is 
probably  p67SRL Other  data  implicate  the  binding  of 
specific factors distinct from p67  sRF. For example, the exis- 
tence of two muscle actin factors,  MAPFI and MAPF2, has 
been described (Walsh and Schimmel,  1987). Each of these 
factors binds to the actin CArG box sequence in preference 
to the c-fos SRE. MAPF1 or p62 is the prominent binding 
activity in nonmuscle ceils and embryonic chicken skeletal 
muscle.  MAPF2, a 35-kD protein,  is restricted to muscle 
cells and found in nuclear extracts prepared from different 
myogenic  cell lines such  as L6, C2, and So18 (Walsh and 
Shimmel,  1988, 1989; Ernst et al., 1991). More recently, a 
family  of four embryo CArG box binding  factors (ECF), 
which differ from p67  s~, have been identified  in Xenopus 
embryos. One of these, ECF1, seems to be related to MAPF1 
and  MAPF2  and  is  the  predominant  binding  activity  in 
cardiac actin-expressing  tissues (Taylor,  1991). Neverthe- 
less, other reports have suggested  that p67  s~ is implicated 
both  in  muscle-specific  gene  expression  and  serum- 
responsive transcription  in Xenopus embryos (Mohun et al., 
1991). 
Using specific antibodies against  p67  s~, we have exam- 
ined the presence and implication of this protein during myo- 
genesis.  We describe p67  s~ mRNA and protein expression 
during the differentiation of two cell lines-the rat myogenic 
cell line L6 and the mouse myogenic cell line C2-revealing 
both expression and specific nuclear localization  of p67  s~ 
in both myoblasts and differentiated myotubes. Moreover, we 
show that p67  sRr is implicated in skeletal muscle differenti- 
ation,  because anti-p67 sRF antibodies microinjected into L6 
or  C2  cells  specifically  prevented  the  myoblast-myotube 
transition  and expression of both the myogenic factor, myo- 
genin, and the skeletal muscle protein, troponin T, a marker 
of the differentiated  state.  These results suggest that p67  s~F, 
in addition to its role in cell proliferation,  is also implicated 
in the transmission  of the differentiation  signal. 
Materials and Methods 
Cell Culture 
The L6G7 subclone was obtained by limited dilution of the myogenic rat 
L6 line, initially isolated by Yaffe (1968). LtG7 cells and myogenic mouse 
C2 line ('gaffe and Saxel,  1977) were routinely grown in growth medium 
(Ham 'FI2/DME [ratio, 2:1] supplemented with 10% FCS and 2 mM gluta- 
mine). To induce terminal differentiation, L6 cells were plated at a density 
of 1 to 5  x  104 cells/cm  2 on plastic dishes in growth medium. After 2 d, 
growth medium  was  replaced  with differentiation medium consisting of 
DME supplemented with  1 #g/mi insulin and 100 #g/mi transferrin. C2 
cells were plated at a density of 5.103 to 104 cells/cm  2 on plastic dishes and 
grown for 2 d before replacing growth medium with DME containing 2% 
FCS. 
From the time of their initial passage into the appropriate differentiation 
medium, differemiation was effectively complete within 6 d for L6 cells and 
3 d for C2 cells. At this time, >60-90% of the cells were differentiated into 
myotubes as assessed by phase microscope analysis. 
Immunofluorescence Microscopy 
Cells growing on 35-mm dishes were fixed in 3.7% (wt/vol) formaldehyde 
in PBS followed by a 30-s extraction in -20~  acetone before rehydration 
in PBS containing 1% BSA. The cellular distribution of p67 saF protein and 
either troponin T or myogenin was analyzed simultaneously by indirect im- 
munofluorescence using a rabbit antiserum raised against a synthetic pep- 
tide derived from the amino acid sequence of p67  s~r (anti-p67  sR~ diluted 
1:100;  Gauthier-Rouvi~re et al.,  1991) and a mouse monoclonal antibody 
against troponin T diluted 1:500 (Amersham, Les Ulis, France) or a mono- 
clonal antimyogenin antibody generously provided by W. Wright (Univer- 
sity of Dallas, Dallas, TX). Primary antibodies diluted in PBS/BSA were 
incubated for 1 h at 37~  After a 15-min wash in PBS, cells were incubated 
with biotinylated anti-rabbit antibody  (Amersham).  Staining for p67  sar 
was revealed by a 30-min incubation with Texas red-streptavidin (Amer- 
sham)  together  with  affinity-purified  fluorescein-conjugated  goat  anti- 
mouse antibodies (Cappel, Organon Technica, Fresnes, France) to visualize 
either troponin T or myogenin staining. Stained cells mounted in Airvo1205 
(15% Airvol 205, Air Products,  Utrecht, the Netherlands, 33%  glycerol, 
0.1% NaN3 in PBS, pH 7) were observed on a microscope (Axiophot; Carl 
Zeiss, Inc., Thornwood, NY) using a planapochromat 40￿  objective. Fluo- 
rescem images were recorded onto TriXpan 400 film (Eastman Kodak Co., 
Rochester, NY) and developed in Diafine (Acufine, Inc.,  Chicago, IL). 
One-Dimensional Gel Electrophoresis  and 
Western Iramunoblotting 
To analyze the protein expression in C2 or L6 cells before or after differenti- 
ation, cells growing on 35- or 60-mm dishes were rinsed twice in PBS and 
solubilized into Laemmli sample buffer (40 mM Tris-HCl, pH 6.8; 5 mM 
DTT,  1% SDS, Z5% glycerol; 0.01% bromophenol blue) by direct addition 
to the dish. After scraping and boiling, the sample (~106 cells) was loaded 
on a 12.5% polyacrylamide gel. After electrophoresis, proteins were trans- 
ferred onto nitrocellulose and blotted with anti-p67  sar~ or antitroponin T 
antibodies (used at dilutions of l:100 and 1:1000, respectively). Primary an- 
tibodies were identified with horseradish peroxidase-conjugated anti-rabbit 
or anti-mouse antibodies and developed with chloronaphtol as previously 
described (Gauthier-Rouvi~re et at.,  1991). 
Northern Blot 
Total RNA was extracted using the guanidium isothiocyanate,/LiC1 proce- 
dare of Cathala et al. (1983). Total RNA (20/~g) was fractionated on 1% 
agarose gels containing 2 M formaldehyde, transferred, and bound to nylon 
membranes (Hybond; Amersham) as described by the supplier. Filters were 
hybridized using the following eDNA probes labeled by random priming: 
human SRE  generously provided by R.  Treisman (ICFR,  London,  UK), 
mouse myogenin (Edmonson and Olson,  1989), and rat GAPDH (Fort et 
al., 1987). Filters were washed twice for 30 rain with 0.2 ￿  SSC, 0.1% SDS 
at 65~  and autoradiographed for 1-5 days at -70~ 
Microinjection 
For microinjection studies, cells growing on plastic dishes were microin- 
jected with anti-p67  sm~ antibodies or, as a control, the anti-p67  sRF antibod- 
ies preincubated with the immunogen peptide or the preimmune serum. In 
all cases, injection solutions contained additional rabbit inert IgG antibod- 
ies  (I  mg/rnl) to serve subsequently in identifying injected cells,  After 
microinjection, cells were placed in differentiation media and returned to 
the incubator for ~/2 h to obtain a maximal level of differentiation. Cells 
were then fixed with formalin, and effects were analyzed by imrnunofluores- 
cence using biotinylated anti-rabbit antibodies followed by subsequent reac- 
tion with Texas red-streptavidin to visualize injected cells and antitroponin 
T  or antimyogenin antibodies to probe for differentiating cells. 
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p6 7  s~F Expression and IntraceUular Localization 
during Myogenesis 
The expression of p67  s~ was investigated  in two different 
cell lines,  a  subelone of the rat myogenic  cells L6 (Yaffe, 
1968) and the mouse myogenic cell line C2 (Yaffe and Saxel, 
1977). In media containing  10% FCS, these cells proliferate 
rapidly without expressing the muscle phenotype. On with- 
drawal of the mitogen, they undergo differentiation such that 
within 3 d for C2 cells or 6 d for L6 cells, 60-90% of cells 
fuse to  form  plurinucleate  myotubes expressing  muscle- 
specific proteins.  The expression and intracellular  localiza- 
tion of p67  s~ protein was analyzed by immunofluorescence 
using  anti-p67 s~ antibodies.  The  specificity of this  anti- 
body has been described elsewhere (Gauthier-Rouvi~re  et 
al.,  1991) and gives a specific nuclear staining  in a variety 
of n-onmyogenic cell lines, showing that p67  s~ is a constitu- 
tive nuclear protein present throughout the cell cycle. 
The two myogenic  cell lines  L6 and C2 were examined 
both  in  the  proliferative  myoblast  stage  and  after  they 
differentiated  into  myotubes.  We  performed  anti-p67 s~ 
staining together with antitroponin  T staining, which consti- 
tutes a good marker of the differentiated  state (Fig.  1). Fig. 
1,  A  and  E  shows  the  immunofluorescence  staining  for 
p67  s~ in L6 and C2 myoblasts, respectively,  where all cells 
are stained throughout the nucleus.  Simultaneous staining 
for troponin T in these cells confirms an absence of expres- 
sion of this marker of differentiation  (Fig.  1, B and F). In 
Fig. 1, C and G, where the cells are in the differentiated myo- 
tube stage, all the nuclei in both the L6 (C) and the C2 (G) 
myotubes show positive staining  for p67  s~,  while at the 
same time extensive cytoplasmic expression of troponin T is 
now present (D and H). These data show that p67  s~ stain- 
ing is nuclear in the two cell lines and present in all the cells, 
both in myoblasts and myotubes, and that the level of p67  s~ 
seems similar between these two stages. Using immunofluo- 
rescence staining  with anti-p67 s~, we have also examined 
the  expression  of p67  s~  in  L6  and  C2  cells during  the 
course of differentiation  (from day 1, when they were placed 
in differentiation  medium, to day 4  (C2) or 6 (L6), when 
differentiation  was nearly complete). In all cases, we were 
unable to detect significant changes or differences in p67  s~ 
staining  level (data not shown). Because the protein level is 
difficult to appreciate accurately by immunofluorescence,  we 
also performed immunoblot analysis on the two cell lines, 
before and after differentiation.  Like in REF 52 cells (an em- 
bryonic rat  fibroblast cell line;  Gauthier-Rouvi&e et al., 
1991), the antibody recognizes a 67-kD band in L6 and C2 
muscle cells and reveals a similar level of SRF expression 
between myoblasts (Fig. 2 A, lanes L6 mb and C2 mb) and 
myotubes (Fig. 2 A, lanes L6 MT and C2 MT). This band 
is abolished by preineubation with the immunogen peptide 
(data not shown). These data also show the specificity of the 
anti-p67  s~ antibody,  which recognizes only p67  s~F in the 
two myogenic  cell lines  used in this study. 
Together, these results demonstrate that p67  s~ protein is 
always present throughout the differentiation  of the two cell 
lines C2 and  L6 without detectable changes in its level. 
These data are in agreement with a previous report of Taylor 
et al. (1989) showing that the amount of CArG box binding 
activity,  biochemically  and  immunologically  similar  to 
HeLa cells p67Sr% was the same in both FAF2 myoblasts 
and myotubes. 
p6 7  s~ raRNA Level in Myoblasts and Myotubes 
To  study tgi7 s~ expression  at the mRNA level,  we per- 
formed Northern blot analysis in proliferative myoblasts and 
differentiated  myotubes. Total mRNA isolated from L6 or 
C2 myoblast cultures before or after differentiation  was sub- 
jeered to RNA blot analysis by probing membranes with the 
human SRF eDNA (a gift from R. Treisman)  and with the 
myogenin eDNA as a marker of differentiation  (Edmonson 
and Olson, 1989). Myogenin expression occurs when myo- 
blasts are triggered to differentiate.  The GAPDH cDNA was 
used to control levels of loading. 
SRF probe reveals two mRNA species at ~2.5 and 4.5 kb 
in C2 and L6 growing  myoblasts  (Fig.  3, lane C2 mb and 
L6 mb) and C2 differentiated myotubes (Fig. 3, lane C2 MT; 
3 d in differentiation  medium composed of DME plus 2 % 
FCS). Similar results have been reported in HeLa cells (Nor- 
man et al.,  1988) and mouse NIH3T3 fibroblasts  (Misra et 
al., 1991). The two mRNA were shown to have identical cod- 
ing sequences differing in the length of their 3' untranslated 
regions (Norman et al., 1988). Surprisingly,  only the 4.5-kb 
mRNA species is  detected in differentiated  L6  myotubes 
(Fig. 3, lane L6 MT1). To ensure that the difference observed 
between C2 and L6 myotubes (two mRNA species for C2 
and only one for L6) was not artifactual,  for example, result- 
ing from the differences in composition of the differentiation 
medium  used  for  the  two  cell  lines  (see  Materials  and 
Methods), differentiation  of L6 cells was also induced by 
placing  L6 cells in C2 differentiation  medium (DME con- 
taining  2 % serum). Under these conditions, differentiation 
occurred in 5-6 days, with 50-70% of cells forming myo- 
tubes. We still observed only a single 4.5-kb mRNA band 
(Fig.  3, lane L6 MT2).  The reason for this difference  be- 
tween the two cell lines (C2 and L6) is unclear. However, the 
absence of detectable expression of the smaller transcript  for 
p67s~ in L6 myotubes is unlikely to be a significant feature 
of the differentiated stage since both species are clearly pres- 
ent in C2 myotubes. Therefore,  this difference between C2 
and L6 myotubes might be related to a difference in the ex- 
pression of myogenic factors (Myf5 in L6 cells, Myf5 and 
MyoD in C2 cells). 
Microinjected Anti-p6 7  sRr Antibodies Block the 
Myoblast-Myotube Transition 
Because the results described above show the continuous ex- 
pression of both p67  s~F protein and mRNA through the pro- 
cess  of muscle  cell  differentiation,  we  have  undertaken 
microinjection experiments  to investigate  the potential  re- 
quirement for p67  sRF during the myoblast-myotube transi- 
tion.  Previous experiments showed  that  p67  sRF activity in 
vivo could be specifically  abolished by microinjection  of 
anti-p67 s~  antibodies  (Gauthier-Rouvi~re  et  al.,  1991). 
Effects of such an injection were analyzed in both L6 and C2 
cells.  C2 or L6 myoblasts were seeded onto plastic dishes 
and allowed to proliferate in growth medium for 2-3 d, when 
they nearly reach confluence.  At this stage, anti-p67 s~ anti- 
bodies were microinjected into myoblasts; 30-60 cells were 
Vandrommc et al. P67  s~ in Muscle Differentiation  1491 Figure 1. Immunolocalization of p67  s~ during differentiation  of L6 and C2 myoblasts.  Using rabbit anti-p67 ss~ serum, the intracellular 
localization of p67  s~ was examined by indirect immunofluorescence in L6 and C2 cells at both the proliferative  myoblast and differen- 
tiated myotube stages. Double immunofluorescence was performed using rabbit anti-p67  sFa~2 serum (diluted  1:100) and mouse monoclonal 
antitroponin T antibodies (diluted  1:500) as primary antibodies on L6 (A-B, D) or C2 (E-H) cells before (,4, B, E, F) or after differentiation 
(C, D, G, H). Shown are immunofluorescence micrographs of growing (,4, B) and differentiated  (C, D) L6 cells stained with anti-p67 sl~ 
(,4, C) and antitropoain T (B, D).  Growing (E, F) and differentiated  (G, H) C2 cells stained  with anti-p67 sR~ and antitroponin T are 
shown (E, G and F, H, respectively).  Bar,  10/~m. 
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ysis  of  p67  s~  in  myoblasts 
and  myotubes.  Total  cell  ex- 
tracts  from 'o106 proliferative 
or  differentiated  C2  or  L6 
cells  were subjected  to elec- 
trophoresis  for  immunoblot- 
ting  with  rabbit  anti-p67 s~ 
antibodies (A) and monoclonal 
mouse antitroponin T antibod- 
ies (B) as described in Materi- 
als and Methods. The arrow in 
A  indicates  the  band  corre- 
sponding  to  p67  sRr.  Lane 
L6mb shows proliferative  L6 
myoblasts,  lane L6MT shows 
differentiated  L6  myotubes, 
lane C2mb shows proliferative 
C2 myoblasts, and lane C2MT 
shows differentiated  C2 myo- 
tubes.  The  arrow  in B  indi- 
cates staining  for troponin T. 
microinjected  in the  same  area.  After microinjection,  the 
differentiation  of the  cells  was  induced  by  replacing  the 
growth  medium  with  the  appropriate  differentiation  me- 
dium.  Cells were further incubated for/>72 h  to allow op- 
timal differentiation; then they were fixed and processed for 
immunofluorescence.  Microinjection  of preimmune  serum 
followed by an identical period of  incubation served as a con- 
trol  for this  experiment.  Microinjected  cells  were  subse- 
quently located by staining with anti-rabbit antibodies as de- 
scribed  in Materials  and  Methods,  and cell differentiation 
was evaluated by monitoring the  expression of troponin T 
using  monoclonal antibodies  against this  myotube-specific 
protein. 
C2 cells constitute a better model than L6 cells for these 
microinjection  experiments  essentially  because  they  dif- 
ferentiate more rapidly, and at the time of fixation (72 h after 
injection), only a minor percentage of cells, evaluated by ex- 
pression of troponin T  and phase contrast,  remained undif- 
ferentiated.  As shown in Fig. 4, in control experiments,  in 
which myoblasts were microinjected with preimmune anti- 
serum, rabbit fluorescent staining (A) was observed in myo- 
tubes  and  mononucleated  cells,  with  50-60%  of injected 
Figure 3.  Northern blot anal- 
ysis  of p67  sRF  transcripts  in 
muscle cells. 20 #g total RNA 
samples were loaded per lane. 
Cultures  were  harvested  ei- 
ther during exponential growth 
(rob)  or  after  differentiation 
(MT);  Northern  blots  were 
performed using human SRF, 
mouse  myogenin,  or  rat 
GAPDH  cDNA  as  probes. 
Shown are autoradiographs of 
hybridization  on  total  RNA 
from proliferative  (lane  C2, 
mb)  and  differentiated  (lane 
C2,  MT) C2 cells,  prolifera- 
tive  L6  myoblasts  (lane  L6, 
rob),  and  L6 cells  differenti- 
ated  into  L6  differentiation 
medium (lane L6, MTI) or C2 
differentiation  medium  (lane 
L6,  MT2)  using  SRF,  myo- 
genin,  and  GAPDH  cDNA 
probes. 
Vandromme et al. P67  s~ in Muscle Differentiation  1493 Figure 4.  Anti-p67  sw injection into myoblasts prevents myoblast-myotube transition and expression of the skeletal muscle protein tro- 
ponin T in C2 cells. To examine the potential role of p67  s~ in the process of muscle differentiation, we injected subconfluent C2 cells 
with anti-p67  sRr antibodies. After injection, cells were placed in differentiation medium and incubated for 72 h before fixation and stain- 
ing for microinjected rabbit antibodies and troponin T, as described in Materials and Methods. Shown are fluorescent images of  the injected 
rabbit antibodies (A, C) or the staining for troponin T (B, D). (A-B) Cells injected with preimmune rabbit antibodies before induction 
of differentiation: the asterisk indicates anti-rabbit  staining found in differentiated myotubes. The same result was obtained when 067  sRF 
antibodies preincubated with the immunogen SRF peptide were used as injection control (data not shown). (C, D) Cells injected with 
affinity-purified  rabbit anti-p67  sRF before induction of differentiation. The injected cells, marked by arrows, all remained in the myoblast 
stage. Bar, 10 tzm. 
cells differentiating into myotubes and/or expressing tropo- 
nin T (B). In contrast, the majority of C2 myoblasts micro- 
injected  with  antibodies  to  p67  sRF  (90-95%  of  injected 
cells) remained in a  mononucleated form (C) without ex- 
pressing the muscle-specific marker troponin T  (D). These 
results were observed four times with 30-60 cells injected 
in each experiment (see Fig.  6 for quantitation). 
The  experiment was  also  done  in  L6  cells.  The  same 
period of incubation after antibody injection was chosen be- 
fore fixation of the cells because 72 h corresponds to a mid- 
point between the half-life of the injected antibodies and the 
time required for differentiation. In contrast with C2 cells, 
72 h was not sufficient to obtain optimal differentiation in L6 
cells.  Nevertheless, the use of conditioned medium as L6 
differentiation medium allowed 40-50% of L6 myoblasts to 
differentiate during this period. As observed for C2 cells, 
when L6 myoblasts were injected with preimmune antibod- 
ies,  anti-rabbit fluorescent staining  was  observed both in 
myotubes and mononucleated cells, with 40-50% of injected 
ceils incorporated into myotubes (Fig.  5, A and B). In all 
cases (>100 cells observed in three experiments), >95% of 
L6 cells  injected with anti-p67  sRF antibodies  remained  in 
mononucleated stage, although most of them were in close 
proximity to or in contact with a myotube, as observed by 
anti-troponin T  staining  (Fig.  5,  C and D;  see Fig.  6  for 
quantitation). 
We  further  investigated  this  inhibitory  effect  of  anti- 
p67  sRv antibodies by looking at their effect on the expres- 
sion of the myogenic factor myogenin, considered one of 
the earliest  markers  for terminal  differentiation.  For that 
purpose, we used monoclonal antimyogenin to monitor the 
expression of myogenin in injected myoblasts. Again, the in- 
The Journal of Cell Biology, Volume 118,  1992  1494 Figure 5.  Anti-p67  sRr injection into L6 myoblasts  prevents their differentiation into myotubes. Subconfluent L6 cells were injected and 
processed as described in Fig. 4. Shown are immunofluorescent  images of the injected rabbit antibodies (A, C) or the staining for troponin 
T (B, D). (A, B) L6 cells, injected with preimmune serum before induction of differentiation, showing a differentiated  myotube (asterisk) 
containing injected marker antibodies. (C, D) L6 cells injected with anti-p67  sr~ before induction of differentiation. The injected cells (ar- 
rows) are mononucleated and in close proximity to a noninjected differentiated myotube. Bar, 10/zm. 
jected cells were identified, after 72 h of incubation in dif- 
ferentiating medium, through immunofluorescence against 
the injected rabbit antibodies.  Fig.  7  shows  the results of 
such  an  experiment  in  L6  myoblasts.  Injection  of anti- 
p67  sR~ antibodies before the induction of differentiation ef- 
fectively prevented the expression of myogenin in injected 
cells (D, E, and F), whereas nuclear myogenin is detected 
in  surrounding  noninjected cells  both  in  mononucleated 
myoblasts  and  differentiating myotubes  (F-). In  contrast, 
when control preimmune antibodies were injected, no in- 
hibitory effect was observed on the expression of myogenin, 
which was detected in 50-60%  of the injected cells (A, B, 
and C), a figure similar to the percentage observed in nonin- 
jected cells.  These results were reproduced and averaged 
from four different sets of microinjection experiments in- 
volving 30-50 injected cells per experiment and show that 
injection of anti-p67  saF prevented the expression  of myo- 
genin in >90% of the injected cells. The same results have 
been obtained with C2 cells, where injected anti-p67  sRF anti- 
bodies also blocked the expression of myogenin. More than 
60 % of  control cells (injected with the preimmune antiserum) 
expressed myogenin, whereas <10 % of anti-p67SRF-injected 
C2 cells were positive for this myogenic factor (see Fig. 8 
for quantitative representation of these data). 
Having shown the ability of anti-p67  sRF antibodies to pro- 
duce an early block in myogenesis, it was important to check 
that such an effect was not resulting from nonspecific long- 
term cytotoxicity of the injected antibodies. In that respect, 
we found that injection of anti-p67  s~ antibodies did not al- 
ter viability of cells because no cellular death was observed; 
>95 % of the injected cells were still alive 72 h after injec- 
tion, a figure similar to the value observed with injection of 
the control antibodies. Furthermore, as an additional control 
experiment, we addressed the ability of injected cells to re- 
tain such functions as adherence, which usually implies a 
good viability of  cells. For that purpose, C2 cells were inocu- 
lated in a small square delineated on a 35-mm dish, injected 
with anti-p67  s~F antibodies, and placed into differentiation 
medium before being returned to the incubator for 72 h. Af- 
ter this period, cells were trypsinized, reseeded on a 35-mm 
dish, and allowed to reattach for 8 h before fixation and stain- 
ing for injected antibodies (anti-rabbit staining) and tropo- 
nin T. Again, >90% of  the injected cells reattached properly 
and did not express the troponin T  differentiation marker, 
showing that injection of anti-p67  s~ did not impair the abil- 
ity of the injected cells to reattach following trypsinization 
(data not shown). In addition, we observed that anti-p67  s~ 
injection into REF52 fibroblasts at the G1 phase did not pre- 
vent the expression of cyclin A (this protein is expressed at 
the onset of S phase;  Gauthier-Rouvi~re, C.,  unpublished 
results)  showing that such an injection of anti-p67  s~ did 
not interfere with essential functions such as transcription 
and translation. 
Taken together, these results clearly show that inhibition 
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Figure 6. Inhibitory effect of anti-p67  sRF injection on the differen- 
tiation of C2 and L6 cells injected as described in Figs. 4 and 5. 
The histogram summarizes the data collected from four (for C2 
cells) and three (for L6 cells) independent sets of experiments; 30 
to 60 cells were injected for each experiment. Percent of  differentia- 
tion refers to the percentage of injected cells expressing  troponin T, 
as shown in Fig. 5. 
of p67  sRF in vivo, through microinjection of anti-p67  sRF an- 
tibodies,  specifically prevented  the  process  of myogenic 
differentiation in L6 and C2 myoblasts. 
Discussion 
This study shows that p67 sRF is expressed constitutively at 
both mRNA and protein levels throughout skeletal myogene- 
sis, with a nuclear localization both in myoblasts and myo- 
tubes, as demonstrated by immunofluorescence  staining with 
anti-p67  s~ antibodies. Furthermore, we showed that p67  sRF 
is required for muscle differentiation, because microinjec- 
tion  of anti-p67  s~  antibodies  into  myoblasts blocks  the 
myoblast-myotube transition. These results, reproduced in 
mouse C2 and rat L6 myogenic cells, demonstrate the gen- 
eral implication of this transcription factor in the process of 
muscle differentiation. 
p6 7  sRr Is Required for Myoblast-Myotube Transition 
The CArG  sequence  CC(A/T)6GG  was  first identified in 
the  c-fos gene promoter as the core of the SRE element 
(Treisman, 1985; Gilman et al., 1986). It was subsequently 
found in many other gen  ~,  including cytoskdetal t- and 
"y-actins, interleukin-2 receptor, Krox 20/1, Krox 20/2, dys- 
trophin, myosin light chain 1/3, and the family of muscle- 
specific o~-actins (Taylor et al.,  1988;  Treisman, 1990).  In 
addition to its well-known function in immediate early gene 
expression, previous work has implicated the CArG boxes in 
muscle-specific transcription (Miwa and Kedes, 1987; Phan- 
Dinh-Tuy et al.,  1988;  Walsh and Shimmel, 1988).  p67 sRF 
participates in the activation of c-fos transcription by direct 
binding to the SRE dement. Using band-shift assays, several 
studies demonstrated that p67  s~ can bind to CArG box se- 
quences from muscle actin promoters, suggesting that this 
factor may also play a role in muscle differentiation (Boxer 
et al.,  1989;  Taylor et al.,  1989;  Tuil et al.,  1990).  Our 
results extend these observations further and clearly demon- 
strate that p67  sRF is implicated in myogenesis: 
(a) p67  sRF expression was not reduced and its cellular lo- 
calization was not affected in the course of the differentiation 
process. It is well documented that other components of the 
proliferative pathways are down-regulated during the course 
of differentiation (for example, cdc2 kinase [Akhurst et al., 
1989],  p21ras [Olson et al., 1987; Sternberg et al.,  1989], 
c-myc [Denis et al., 1987],  and c-los [Rahm et al., 1989]). 
(b)  Inhibition of p67  s~  activity following injection of 
anti-p67  s~  antibodies into myoblasts prevented their dif- 
ferentiation into myotubes and expression of both myogenin 
and the muscle-specific marker troponin T. The inhibition of 
p67  s~ activity in fibroblasts has previously been shown to 
prevent cell cycle progression by stopping cells during the 
G1 phase, the period that precedes DNA synthesis (Gauthier- 
Rouvi~re et al., 1991). The transition from the proliferative 
to the differentiated state is characterized by withdrawal of 
myocytes from the cell cycle in the G1 phase (Nadal-Ginard, 
1978;  Compton and Konigsberg,  1988).  If p67 s~ was ex- 
clusively implicated in cell proliferation, a likely prediction 
would be that inactivation of cellular p67 s~ will induce the 
cells to commit into the differentiation pathway. We found 
that this was not the case; instead, it resulted in an inhibition 
of the differentiation pathway. 
The fact that all cells microinjected with anti-p67  s~ re- 
mained in a mononucleated state and did not express myo- 
genin, which marks the activation of the muscle differentia- 
tion program (Edmonson and Olson,  1989;  Wright et al., 
1989),  suggests that p67  sRr is required early in the differen- 
tiation process. One potential CArG box has been identified 
in the myogenin promoter.  However,  the (A/T)6  stretch in 
that case is interrupted in the middle by a C/G pair, and it 
has been shown in a minimal test promoter that the myogenin 
CArG element, isolated from its promoter and cloned up- 
stream from the c-fos TATA element with a reporter gene, 
was not functional both in muscle and nonmuscle cells (San- 
toro and Walsh, 1991). This may imply that the inhibitory 
effect of anti-p67  s~ on myogenin expression results from an 
indirect pathway whereby p67  s~ function would be impli- 
cated upstream. 
How Could a Single Protein Account 
for the Regulation of Serum-responsive and 
Muscle-specific Transcription? 
Our results show that, in addition to its role in cell cycle 
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Figure 8.  Inhibitory effect of anti-p67  s~ injection on myogenin 
expression in C2 and L6 cells. The histogram summarizes the data 
collected from four different sets of experiments for each cell line; 
30 to 50 ceils were injected for each experiment. Percent of myo- 
genin expression refers to the percentage of cells expressing myo- 
genin as monitored by immunofluorescence  double staining, as de- 
scribed in Fig. 7. 
progression,  p67 sRF participates  in  the  expression  of the 
muscle-specific  program.  The  following  question  thus 
arises: How can the same factor be involved in both tran- 
scriptional activation of proliferative immediate early genes 
such as c-fos or/~-actin, and in the expression of muscle- 
specific  genes  such  as  skeletal  and  cardiac  o~-actin,  a 
differentiation-dependent process  that requires  the down- 
regulation of genes implied in cellular growth? A  simple 
view  is  that p67 sRF activity is  altered in  a  tissue-specific 
fashion, p67 s~ is a phosphoprotein; phosphorylation medi- 
ated by casein kinase II is thought to play a role in the regula- 
tion  of p67  sRF  binding  to  the  SRE  sequence  throughout 
growth factor stimulation. Differentiation in culture is trig- 
gered  by  depletion  of  growth  factors  from  the  culture 
medium.  This  implies  dramatic  modifications  in  signal 
transduction, with particular changes in protein kinase ac- 
tivities (Adamo et al.,  1989;  Kelvin et al.,  1989;  Tollefsen 
et al.,  1989).  Differential postranslational modifications of 
p67  sRr may thus confer different transcriptional specificities 
to this protein, particularly by changing its affinity to the 
CArG sequence and/or its binding with various cofactors. In 
this respect,  transcriptional activation acting at the CArG 
box may involve interactions of SRF with different nuclear 
factors. One such factor, p62  rcF, binds p67 sRF at the c-fos 
SRE and has been shown to be required for full transcrip- 
tional  activation of the  c-fos  gene  (Shaw  et  al.,  1989). 
p62  rcF has been proposed to be a physiological substrate for 
the protein kinase C pathway, providing an additional level of 
control for SRF transcriptional activity (Graham and Gil- 
man, 1991). According to this view, different accessory pro- 
teins binding to p67 ssr may be involved in the tissue-specific 
expression acting at the CArG boxes. It will be of interest to 
determine whether such a heteromultimeric complex with 
p67 s~ could be detected in a state- or tissue-specific fash- 
ion.  In addition, the  sequence flanking the CC(A/T)tGG 
motif  may also be important in the regulation of such interac- 
tions. By methylation interference and mutational analysis, 
p62  ~F has been shown to bind inside the SRE 5 bp upstream 
from the CC(A/T)tGG core sequence (Shaw et al.,  1989; 
Graham and Gilman,  1991). Furthermore, in light of the 
numerous CArG binding factors actually described, a com- 
plementary mechanism of regulation could involve competi- 
tion between p67  s~ and other proteins for binding to the 
CArG element. In this respect, a recent study reported that 
F-ATC1 (also called MAPF1 or p62) may act as a repressor 
of skeletal ot-actin gene transcription, whereas SRF acts as a 
positive transcription factor (Lee et al., 1991). As described, 
F-ATC1 is abundantly present in myoblasts; its level reduces 
during myogenic differentiation, whereas the level of p67  sRF 
remains constant throughout myogenesis (Taylor et al., 1989). 
Therefore, the change in this ratio in favor of p67 sRr during 
the course of differentiation may allow p67  s~ to transacti- 
vate muscle-specific genes. 
Finally, the CArG box sequences may act in concert with 
other cis-acting  sequences to accomplish coordinate tran- 
scriptional  regulation  during  myogenesis.  A  number  of 
muscle-specific sequences have been described, including 
the CANNTG box (the E-box motif). The E box is the bind- 
ing site for the recently identified family of MyoD1 myogenic 
factors. In contrast to p67  s~, these factors (MyoD, Myf5, 
myogenin, MRF4)  are expressed  only in skeletal muscle 
cells.  Their  role  in  muscle-specific  expression  is  well 
documented (Weintraub et al., 1991). Functional E-box se- 
quences are localized in proximity to the CArG box in many 
muscle-specific genes, suggesting that the CArG box may 
function as a constitutive and prerequisite promoter element 
and, as such, does not directly contribute to the absolute 
muscle-specific regulation. However, such a model does not 
exclude the implication of p67  s~ in muscle differentiation, 
and, as shown by Sartorelli et al. (1990),  both MyoD, Spl 
(a ubiquitous transcription regulatory factor), and p67  sRF 
(or  SRF-related proteins)  bind  specifically to the human 
cardiac o~-actin gene and are involved in its activation. 
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